September 14, 2023 11:37 AM EDT
News Briefing
AI

Ab­cam founder Jonathan Mil­ner op­pos­es Dana­her buy­out; First Wave tries to find new life in Sanofi drug

Ayisha Sharma

News Reporter

Lei Lei Wu

News Reporter

Ab­cam’s founder Jonathan Mil­ner plans to vote against Dana­her’s $5.7 bil­lion ac­qui­si­tion of the com­pa­ny, he an­nounced Thurs­day.

Mil­ner owns …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times